9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma

Condition Lung Cancer - Malignant Pleural Mesothelioma Estimated Enrollment: 27 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: UCL/12/0158|CMS # 1995|A15183|2012-001598-10|TBC Study First Received: April 30, 2012 Last Updated: October 26, 2016 Estimated Primary Completion Date: September 2017 Primary Outcome Measures: Maximum Tolerated Dose of Ganetespib|Progression Free Survival Sponsors and Collaborators: University College, London|Cancer Research UK Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01590160...

Continue reading

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

Condition Lung Cancer|Mesothelioma Estimated Enrollment: 28 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: 2014-0497|NCI-2014-02568 Study First Received: November 11, 2014 Last Updated: February 15, 2017 Estimated Primary Completion Date: May 2021 Primary Outcome Measures: Disease Control Rate (DCR)|Response Rate Sponsors and Collaborators: M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02293005...

Continue reading

SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

Condition Mesothelioma|Adenocarcinoma of Lung|Pancreatic Neoplasms Estimated Enrollment: 55 Age Group: 18 Years to 99 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment Study ID Numbers: 110160|11-C-0160 Study First Received: May 27, 2011 Last Updated: April 20, 2017 Estimated Primary Completion Date: August 3, 2016 Primary Outcome Measures: Objective response rate stratified by tumor type|SS1P antibody formation|Grade and description of adverse events|determine RP2D in drug lot FIL129J01|Overall survival|Progression-free survival|Duration of response Sponsors and Collaborators: National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01362790...

Continue reading

Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma

Condition Malignant Peritoneal Mesothelioma Estimated Enrollment: 35 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 12-0032|NCI-2012-00332 Study First Received: May 3, 2012 Last Updated: June 24, 2016 Estimated Primary Completion Date: June 2017 Primary Outcome Measures: Objective response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1|PFS|OS|Toxicity in terms of adverse events per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.0|Disease control rate - SD + PR + CR|Percentage of patients who have activating EGFR mutations among all screened patients Sponsors and Collaborators: University of...

Continue reading

Combination Gene Transfer and Chemotherapy

Condition Mesothelioma Estimated Enrollment: 40 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: UPCC 02510; 811318 Study First Received: May 6, 2010 Last Updated: October 10, 2016 Estimated Primary Completion Date: October 2013 Primary Outcome Measures: To determine the safety of administering intrapleural SCH 721015, Ad.hIFN-alpha2b (Adenoviral-mediated Interferon-alpha) in combination with chemotherapy for the management of MPM.|To estimate objective response rates and distribution|Time to Progression Sponsors and Collaborators: Abramson Cancer Center of the University of Pennsylvania Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01119664...

Continue reading

Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 60 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: ADU-CL-02 Study First Received: August 23, 2012 Last Updated: January 25, 2017 Estimated Primary Completion Date: June 2017 Primary Outcome Measures: Number of subjects reporting adverse events|Induction of immune response to mesothelin by enzyme-linked immunosorbent spot (ELISPOT) assay|Objective tumor response|Time to progression|Serum mesothelin as correlate of therapeutic response Sponsors and Collaborators: Aduro Biotech, Inc. Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01675765...

Continue reading

Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 80 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: EF-23 Study First Received: March 19, 2015 Last Updated: March 28, 2017 Estimated Primary Completion Date: February 2018 Primary Outcome Measures: Overall Survival|Progression Free Survival|Response Rate|Toxicity Sponsors and Collaborators: NovoCure Ltd. Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02397928...

Continue reading

Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM).

Condition Mesothelioma, Malignant Estimated Enrollment: 108 Age Group: 18 Years to 99 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment Study ID Numbers: MORAb-009-201 Study First Received: January 14, 2015 Last Updated: February 8, 2017 Estimated Primary Completion Date: September 2017 Primary Outcome Measures: Overall Survival (OS)|Progression Free Survival (PFS)|Objective Response Rate [ORR]|Duration of response (DR)|Disease control rates (DCR)|Duration of disease control (DDC)|Health related quality of life (QOL)|Duration of Performance Status Maintenance (DPSM)|Safety and tolerability as a measure of number of participants with Adverse Events (AEs)/Serious Adverse Events (SAEs)|Pharmacokinetic (PK) and pharmacodynamic (PD) profile Sponsors and Collaborators: Morphotek Result Received: No Study Results Posted Website...

Continue reading

Dasatinib in Resectable Malignant Pleural Mesothelioma

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 60 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 2006-0935|NCI-2010-01505|W81XWH-07-1-0306 Study First Received: March 27, 2008 Last Updated: September 23, 2016 Estimated Primary Completion Date: March 2018 Primary Outcome Measures: Modulation of biomarker p-Src Tyr419 expression|Progression-free Survival Sponsors and Collaborators: M.D. Anderson Cancer Center|Bristol-Myers Squibb|United States Department of Defense Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00652574...

Continue reading

Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy

Condition Malignant Mesothelioma Estimated Enrollment: 68 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: CALGB-30901|U10CA180821|U10CA031946|CDR0000667496 Study First Received: March 11, 2010 Last Updated: March 6, 2017 Estimated Primary Completion Date: July 2017 Primary Outcome Measures: Progression-free survival|Overall survival|Frequency of responses|Toxicity Sponsors and Collaborators: Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01085630...

Continue reading